SCHEDULE 13G/A: BlackRock Discloses Reduced Passive Stake in Cardiff Oncology, Inc. Below 5% Threshold

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.3% passive beneficial ownership stake in Cardiff Oncology, Inc. as of December 31, 2024.

Summary

• BlackRock, Inc. filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Cardiff Oncology, Inc.
• As of December 31, 2024, BlackRock beneficially owned an aggregate of 2,840,909 shares of Cardiff Oncology, Inc. common stock.
• This ownership represents 4.3% of the total outstanding common stock of Cardiff Oncology, Inc.
• BlackRock holds sole voting power over 2,810,955 shares and sole dispositive power over 2,840,909 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to BlackRock's stake falling below the 5% threshold, suggesting a reduction in their position. While it's a routine filing, the decrease in ownership by a major institutional investor can be perceived as a negative signal.

Positives

• BlackRock, a prominent institutional investor, continues to hold a significant stake in Cardiff Oncology, Inc., indicating ongoing interest in the company.
• The filing explicitly states that the securities are held in the ordinary course of business and not for control purposes, suggesting a stable, passive investment approach.

Negatives

• BlackRock's beneficial ownership percentage has decreased to 4.3%, falling below the 5% threshold, which implies a reduction in their stake in Cardiff Oncology, Inc.

Risks

• The reduction in BlackRock's stake to below 5% could be interpreted by the market as a negative signal, potentially impacting investor sentiment and the company's share price.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of institutional ownership. It indicates that BlackRock, a major asset manager, continues to hold a stake in Cardiff Oncology, Inc., though it has reduced its position to below the 5% threshold. This type of passive investment disclosure does not typically provide insights into broader industry trends or competitive positioning beyond the fact that a significant institutional investor is involved with the company.

Stakeholder Impact

• Shareholders: The reduction in BlackRock's stake to below 5% might be viewed as a negative signal, potentially influencing investor sentiment and share price.

Key Dates

Recommendation

Keywords

Cardiff Oncology Inc., BlackRock Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Passive Investment, Ownership Disclosure